Hemosiderosis: Difference between revisions

	Hemosiderosis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hemosiderosis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
CT
MRI
Echocardiography or Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hemosiderosis On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hemosiderosis All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hemosiderosis
CDC on Hemosiderosis
Hemosiderosis in the news
Blogs on Hemosiderosis
Directions to Hospitals Treating Hemosiderosis
Risk calculators and risk factors for Hemosiderosis

	Hemosiderosis;
ICD-9	516.1
OMIM	178550
DiseasesDB	29717

VisualWikitext

Latest revision as of 08:15, 28 September 2020

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Roghayeh Marandi

Synonyms and keywords: Idiopathic pulmonary hemosiderosis; IPH; hemosiderin accumulation; Pulmonary hemosiderosis; Pulmonary haemosiderosis; Essential brown induration of lung; Brown induration of lung; Ceelen-Gellerstedt syndrome

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Hemosiderosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Treatment

Case Studies

Case #1

Related Chapters

Transfusion hemosiderosis

Template:WH Template:WS

@@ Line 1: / Line 1: @@
 __NOTOC__
+{{Infobox_Disease
+ | Name           = {{PAGENAME}}
+ | Image          =
+ | Caption        =
+ | DiseasesDB     = 29717
+ | ICD10          =
+ | ICD9           = {{ICD9|516.1}}
+ | ICDO           =
+ | OMIM           = 178550
+ | MedlinePlus    =
+ | MeshID         =
+}}
 {{Hemosiderosis}}
-{{CMG}}
+{{CMG}} [[Roghayeh Marandi]]
-==Overview==
+{{SK}} Idiopathic pulmonary hemosiderosis; IPH; hemosiderin accumulation; Pulmonary hemosiderosis; Pulmonary haemosiderosis; Essential brown induration of lung; Brown induration of lung; Ceelen-Gellerstedt syndrome
-'''Hemosiderosis''' is a condition affecting the [[lungs]] which results in bleeding from tiny [[Pulmonary alveolus|alveolar]] [[capillaries]].
+==[[Hemosiderosis overview|Overview]]==
-== Background ==
+==[[Hemosiderosis historical perspective|Historical Perspective]]==
-Hemosiderosis is an uncommon or rare condition in which bleeding in the lungs causes additional problems especially a collection of [[iron]] (FE) which, in itself causes additional lung damage. Iron is an essential component of a [[hemoglobin]] molecule. This molecule is responsible for transporting [[Oxygen]] through the blood stream and to the individual [[cell (biology)|cell]]s. Such transport is essential for celluar respiration to occur and for life to continue.
-=== Other names ===
+==[[Hemosiderosis classification|Classification]]==
-*Idiopathic Pulmonary hemosiderosis
-*IPH
-*[[hemosiderin]] accumulation
-=== Related or similar conditions ===
+==[[Hemosiderosis pathophysiology|Pathophysiology]]==
-There are many pulmonary problems that may seem to mimic hemosiderosis but do not necessarily include the deposits of iron into the lung. The deposition of iron in the lungs, occurring in the form of [[hemosiderin]], is the defining characteristic of this illness. These other conditions may occur separately or together with hemosiderosis.
-:*[[Pulmonary Fibrosis]]
-:*Adult Respiratory Distress Syndrome (ARDS)
-:*Immune Complex Disease
-:*intra-alveolar bleeding
-== Etiology ==
+==[[Hemosiderosis causes|Causes]]==
-Hemosiderosis can occur either as a primary lung disorder or as the sequela to other pulmonary, cardiovascular or immune system disorder.
-*PH1 involves PH with circulating anti-GMB antibodies.
-*PH2 involves PH with immune complex disease such as [[systemic lupus erythematosus]], SLE.
-*PH3 involves no demonstrable immune system involvement.
-== Survival ==
+==[[Hemosiderosis differential diagnosis|Differentiating Hemosiderosis from other Diseases]]==
-Death may occur rapidly with acute, massive pulmonary bleeding or over longer periods as the result of continued pulmonary failure and left heart failure.
-== See also ==
+==[[Hemosiderosis epidemiology and demographics|Epidemiology and Demographics]]==
+==[[Hemosiderosis risk factors|Risk Factors]]==
+==[[Hemosiderosis screening|Screening]]==
+==[[Hemosiderosis natural history, complications and prognosis|Natural History, Complications and Prognosis]]==
+==Diagnosis==
+[[Hemosiderosis history and symptoms|History and Symptoms ]] | [[ Hemosiderosis physical examination|Physical Examination]] | [[Hemosiderosis laboratory findings|Laboratory Findings]] | [[Hemosiderosis electrocardiogram|Electrocardiogram]] | [[Hemosiderosis chest x ray|Chest X Ray]] | [[Hemosiderosis CT|CT]] | [[Hemosiderosis MRI|MRI]] | [[Hemosiderosis echocardiography or ultrasound|Echocardiography or Ultrasound]] | [[Hemosiderosis other imaging findings|Other Imaging Findings]] | [[Hemosiderosis other diagnostic studies|Other Diagnostic Studies]]
+==Treatment==
+[[Hemosiderosis medical therapy|Medical Therapy]] | [[Hemosiderosis surgery |Surgery]] | [[Hemosiderosis primary prevention|Primary Prevention]] | [[Hemosiderosis secondary prevention|Secondary Prevention]] | [[Hemosiderosis cost-effectiveness of therapy|Cost-Effectiveness of Therapy]] | [[Hemosiderosis future or investigational therapies|Future or Investigational Therapies]]
+==Case Studies==
+[[Hemosiderosis case study one|Case #1]]
+== Related Chapters ==
 * [[Transfusion hemosiderosis]]